Company intelligence / Profile preview

Hangzhou Tianji Jishi Biotechnology

Hangzhou, Zhejiang, Chinaphecdamed.com ↗

Ownership: Private
Development stage: Other

Overview

Hangzhou Tianji Jishi Biotechnology is a private Chinese biotech founded in August 2021 focused on advancing mitochondrial research through novel small molecule mitophagy inducers. Their lead candidate, TJ0113, has reached phase 2 clinical trials for depressive disorder and Parkinson’s disease and earlier stages for several other neurological and metabolic conditions. The company aims to become a leader in innovative biopharmaceuticals targeting diseases with unmet needs related to mitochondrial dysfunction. No published clinical results as of June 2025.

Therapeutic areas: NephrologyPsychiatryNeurologyCardiovascular
Modalities: Small moleculeMitophagy inducers
Industry: Biotech

Drug pipeline

2 assets

TJ0113

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Hangzhou Tianji Jishi Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Tianji Jishi Biotechnology.